Home > Pulmonology > ERS 2020 > COVID-19 and the Lung > COVID-19 vaccines: An ongoing race

COVID-19 vaccines: An ongoing race

Presented By
Prof. George Karakiulakis, Aristotle University of Thessaloniki, Greece
ERS 2020
Worldwide, several hundred COVID-19 vaccine candidates are currently under investigation; some of them already in phase 3 trials. Hopefully approved as of 2021, vaccines may help to fight the COVID-19 pandemic [1]. The development of vaccines differs somewhat from drug development: study participants are healthy volunteers, and the number of participants may be as high as 60,000 in phase 3 testing. Main primary outcomes are safety, tolerability and, especially in phase 3 trials, immunogenicity. The different types of vaccines currently being developed include DNA- or mRNA-based technologies, attenuated or inactivated viruses, virus-like particles as well as replicating and non-replicating viral vectors expressing SARS-CoV-2 proteins. “Both the number and the procedures towards a development of an effective vaccine for COVID-19 are unprecedented,” stated Prof. George Karakiulakis (Aristotle University of Thessaloniki, Greece). A recent review from S...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on